Group 1 - The company held its second board meeting on February 10, 2026, where it approved several key proposals, including adjustments to its fundraising investment structure [1][2][4] - The board approved the addition of a new sub-project "YF550" under the "New Drug Research and Development Project" while maintaining the total investment amount unchanged [2][12] - The board also approved the establishment of a "Market Value Management System" to enhance investor returns and protect investor interests [5][6] Group 2 - The company plans to increase funding for the D-2570 project, a TYK2 inhibitor for treating autoimmune diseases, by approximately 23,210.95 million RMB to support ongoing clinical trials [16][24] - Additional funding of 4,720.00 million RMB will be allocated for the clinical research of YF087, a candidate drug in the preclinical stage [18][25] - The company will also invest 4,290.00 million RMB in YF550, another candidate drug, to prepare for its Phase I clinical trial [19][25] Group 3 - The adjustments in funding are aimed at optimizing resource allocation and ensuring that the investment aligns with the company's research and development strategy [23][26] - The market for autoimmune disease treatments is projected to grow significantly, with the global market expected to reach approximately 194.8 billion USD by 2030, indicating a strong demand for innovative therapies [27][28] - The company is focusing on developing drugs that target unmet clinical needs, particularly in the areas of autoimmune diseases and gout, which are seeing rising patient numbers [29][30]

Core Viewpoint - The company has approved an internal restructuring of its fundraising investment projects to optimize the investment structure for its "new drug research and development projects" while keeping the total fundraising amount unchanged [1] Investment Structure Adjustment - The company will add the preclinical candidate drug "YF550" as a sub-project and reallocate funds among various sub-projects [1] - An additional investment of 232.1095 million yuan will be allocated to the oral TYK2 inhibitor D-2570 project to advance clinical trials for multiple autoimmune diseases, including psoriasis and ulcerative colitis [1] - New investments of 47.2 million yuan, 42.9 million yuan, and 20 million yuan will be made for the preclinical projects YF087, YF550, and exploratory research, respectively [1] - Funding for the URAT1 inhibitor D-0120 project will be reduced by 342.2095 million yuan [1] Strategic Focus - The adjustments aim to concentrate resources on core pipelines with faster research and development progress and greater market potential to enhance funding efficiency and accelerate product development [1] - The proposal is subject to approval at the company's shareholder meeting [1]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for four companies, including Yifang Biotechnology, which is required to clarify compliance operations related to safety production [1] - Yifang Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The CSRC has requested Yifang Biotechnology to provide legal opinions regarding its business scope and whether it involves restricted foreign investment areas, as well as compliance with foreign investment policies [1] Group 2 - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotizumab and Gexorase), two core products in clinical stages (D-2570 and Terysqun), one clinical candidate (Dabinoside), and three preclinical candidates (YF087, YF550, and YF057) [2]

Group 1 - The core viewpoint of the news is that Yifang Biotechnology (Shanghai) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - Yifang Biotechnology is a research-driven biopharmaceutical company based in China, focusing on significant diseases with unmet needs, including oncology, autoimmune diseases, and metabolic diseases [1] - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, which includes two commercialized products (BPI-D0316 and D 1553), two core products in clinical stages (D-2570 and D-0502), one clinical candidate (D-0120), and three preclinical candidates (YF087, YF550, and YF057) [1]

Group 1 - Longhang Asset recently conducted research on Yifang Bio, highlighting the latest progress of several investigational drugs [1] - D-2570 is planned for clinical exploration in multiple autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - The drug Gesorex (brand name Anfangning) received approval from the National Medical Products Administration for the treatment of advanced non-small cell lung cancer (NSCLC) in adults with KRS G12C mutations, with multiple clinical studies ongoing [1] - D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - D-0120 has completed Phase IIb clinical trials, while preclinical studies for YF087 and YF550 have made progress [1] Group 2 - Longhang Asset Management Company is a professional asset management firm based in Shanghai, with a core team possessing 18 years of industry investment experience [2] - The company adheres to a value investment philosophy, utilizing various financial tools to manage client assets for sustainable growth [2] - Longhang Asset emphasizes research-driven investment and the importance of a rigorous scientific investment process [2]

Group 1 - Qianyi Investment recently conducted research on Yifang Biotechnology, highlighting the latest progress of several investigational drugs [1] - D-2570 is planned for clinical exploration in multiple autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - Gexuolei Tablets (brand name Anfangning) received approval from the National Medical Products Administration for market launch in November 2024, targeting adult patients with advanced non-small cell lung cancer harboring KRS G12C mutations who have undergone at least one systemic treatment [1] - D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - D-0120 has completed Phase IIb clinical trials, while preclinical studies for YF087 and YF550 have made progress [1]

Group 1 - Xin Yuan Fund recently conducted research on a listed company, Yifang Bio, discussing the latest progress of multiple drugs under development [1] - Drug D-2570 is planned for clinical exploration in various autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - The drug Gesorex (brand name Anfangning) is expected to be approved by the National Medical Products Administration for advanced non-small cell lung cancer (NSCLC) patients with KRS G12C mutation by November 2024, with multiple clinical studies ongoing [1] - Drug D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - Drug D-0120 has completed Phase IIb clinical trials, while preclinical studies for YF087 and YF550 have made progress [1] Group 2 - Xin Yuan Fund was established in 2013, with a total asset management scale of 212.33 billion yuan, ranking 35th out of 210 [2] - The asset management scale for non-monetary public funds is 140.64 billion yuan, also ranking 35th out of 210 [2] - The fund manages 162 public funds, ranking 47th out of 210, with 22 public fund managers, ranking 63rd out of 210 [2] - The best-performing public fund product in the past year is Xin Yuan Guozheng 2000 Index Enhanced A, with a latest net value of 1.23 and a growth of 60.06% over the past year [2] - The latest public fund product raised by Xin Yuan is Xin Yuan Science and Technology AI Index Initiated A, with a subscription period from July 25, 2025, to August 8, 2025 [2]

Core Viewpoint - The company is committed to enhancing operational efficiency and management quality through its 2025 "Quality Improvement and Efficiency Enhancement" action plan, focusing on innovation in drug development and protecting the rights of investors, especially small and medium-sized investors [1][12]. Group 1: Business Strategy and Development - The company aims to accelerate the layout of its core pipeline, focusing on major diseases such as cancer, metabolic disorders, and autoimmune diseases, with a commitment to developing innovative drugs with independent intellectual property rights [1][2]. - The company has two authorized products on the market, one in the registration clinical trial stage, two in Phase II clinical trials, and multiple preclinical projects, indicating a strong position in research and development [2]. - The company plans to advance the clinical research of its D-2570 product, which has shown promising results in Phase II trials for psoriasis, and will explore its potential in other autoimmune diseases [2][3]. Group 2: Research and Development Capabilities - The company has established a comprehensive R&D system that enhances the success rate of its products and shortens drug development cycles through precise target selection and clinical development processes [2][4]. - The company has a core R&D team with over 20 years of experience in multinational pharmaceutical companies, which strengthens its capabilities in drug design and clinical trial execution [4][5]. - The company has applied for 370 domestic and international invention patents, with 129 granted, ensuring the commercial value of its innovations and reducing potential patent infringement risks [6]. Group 3: Team and Talent Management - The R&D team constitutes over 90% of the company's workforce, with leaders possessing extensive industry experience, which is crucial for the drug development process [7]. - The company plans to implement a new round of equity incentive plans to attract and retain talent, aligning the interests of shareholders and the core team [7]. Group 4: Financial Management and Fund Utilization - The company is focused on improving the efficiency of its fundraising projects and has made adjustments to its headquarters construction project to better meet R&D needs [8]. - In 2025, the company will increase investment in new drug R&D projects, aiming to enhance the efficiency of clinical trials and expand its clinical pipeline [8]. Group 5: Corporate Governance and Compliance - The company is revising its governance structure, including the cancellation of the supervisory board and the enhancement of the board's responsibilities to improve oversight and protect investor rights [9][17]. - The company emphasizes the importance of internal controls and compliance with relevant laws and regulations to ensure effective management of significant matters [9]. Group 6: Information Disclosure and Investor Relations - The company is committed to enhancing the quality of information disclosure and actively engages with investors through various communication channels [10][11]. - The company plans to conduct at least three performance briefings annually to maintain transparency and keep investors informed about its operations and financial status [11].